Last reviewed 2026-04-20 · How we verify

Caducid (FLUORESONE)

Phase 2 active Small molecule

Caducid (generic name: FLUORESONE) is a drug. It is currently in Phase 2 development.

Unfortunately, there is not enough information to provide a one-sentence summary of Caducid's mechanism of action.

Caducid, also known as Fluoresone, is a small molecule drug with unknown target and drug class. Its commercial status is unclear, and it is not known if it is FDA approved or off-patent. There is limited information available on its approved indications, half-life, bioavailability, and generic manufacturers. Further research is needed to understand the full scope of Caducid's use and characteristics. As a result, key safety considerations and mechanism of action are also unclear.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	FLUORESONE
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 2

Mechanism of action

Unfortunately, there is not enough information to provide a plain English explanation of Caducid's mechanism of action.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Caducid CI brief — competitive landscape report
Caducid updates RSS · CI watch RSS

Frequently asked questions about Caducid

What is Caducid?

Caducid (FLUORESONE) is a Small molecule drug.

How does Caducid work?

Unfortunately, there is not enough information to provide a one-sentence summary of Caducid's mechanism of action.

What is the generic name of Caducid?

FLUORESONE is the generic (nonproprietary) name of Caducid.

What development phase is Caducid in?

Caducid is in Phase 2.

Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing